by Truveta staff | Jun 17, 2024 | Data, News, Technology
Truveta now offers regulatory and audit capabilities to support our customers for real-world evidence (RWE) submissions to the Food and Drug Administration (FDA) and other global regulatory authority decisions. These regulatory grade capabilities advance Truveta’s...
by Truveta staff | Mar 11, 2024 | Research
Each year, approximately 900,000 patients in the US are affected by a pulmonary embolism (PE), a blood clot causing a blockage in one or more pulmonary arteries in the lungs. PE is a leading cause of in-hospital death in the US, and acute PE – a sudden blockage...
